Skip to Main Content

Hello, everyone, and how are you today? We are doing just fine, thank you, despite a busy schedule caused by a road trip to the Woodstock-like gathering of biotech types. As you might imagine, this requires finding cups of stimulation at regular intervals. Perhaps you can relate. After all, this is an exceedingly busy few days, yes? Well, wherever you are or whatever you may be doing, feel free to join us. Firing up the neurons can be helpful. On that note, here are some tidbits to help you along. Hope your day goes well and do drop us a line if something interesting pops up …

A group of shareholders, including several founding family members of Takeda Pharmaceutical (TKPYY), are trying to derail the $62 billion acquisition of Shire (SHPG), blasting the deal as “the height of madness,” The Financial Times reports. The dissidents, who hired a former UBS analyst to back their campaign, hold 1 percent of Takeda stock, giving them little real power to overturn the takeover. But their offensive has drawn outsized attention in a country where founding family voices hold emotional sway over votes of mom-and-pop investors, who account for a quarter of Takeda shareholders.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!